Show simple item record

dc.contributor.authorJøraholmen, May Wenche
dc.contributor.authorBasnet, Purusotam
dc.contributor.authorAcharya, Ganesh
dc.contributor.authorSkalko-Basnet, Natasa
dc.date.accessioned2018-04-03T09:09:10Z
dc.date.available2018-04-03T09:09:10Z
dc.date.issued2017-01-11
dc.description.abstractRecent studies regarding mucosal drug delivery indicate that nanosystems with surface-available polyethylene glycol (PEG) are able to penetrate mucus barrier, assure closer contact with the epithelium, and improve drug delivery to vagina. In the present work, we developed the mucus-penetrating PEGylated liposomes containing interferon alpha-2b (IFN α-2b), destined to provide localized therapy for human papilloma virus (HPV) vaginal infections. The PEGylated liposomes were of a mean size of 181 ± 8 nm, bearing a negative zeta potential of – 13 mV and an entrapment efficiency of 81 ± 10%. In vitro release experiments on model membrane showed a nearly non-existent IFN α-2b release from both the control and liposomally-associated IFN α-2b. However, the ex vivo penetration studies performed on the vaginal tissue obtained from pregnant sheep, showed the clear elevated IFN α-2b penetration from PEGylated liposomes as compared to the control. Furthermore, mucin studies confirmed the absence of interaction between the PEG-modified liposomes and mucin, confirming their ability to penetrate mucus and reach the deeper epithelium. The system holds a promise in improving topical delivery of IFN α-2b through enhanced efficacy of local anti-viral therapy.en_US
dc.descriptionPublished version available in <a href=https://doi.org/10.1016/j.ejpb.2016.12.029> European journal of pharmaceutics and biopharmaceutics. 2017;113:132-139</a>.en_US
dc.identifier.citationJøraholmen, M. W., Basnet, P., Acharya, G., Skalko-Basnet, N. (2017). PEGylated liposomes for topical vaginal therapy improve delivery of interferon alpha. European journal of pharmaceutics and biopharmaceutics. 113:132-139en_US
dc.identifier.cristinIDFRIDAID 1425636
dc.identifier.doi10.1016/j.ejpb.2016.12.029
dc.identifier.issn0939-6411
dc.identifier.issn1873-3441
dc.identifier.urihttps://hdl.handle.net/10037/12458
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalEuropean journal of pharmaceutics and biopharmaceutics
dc.rights.accessRightsopenAccessen_US
dc.subjectVaginal therapyen_US
dc.subjectPEGylated liposomesen_US
dc.subjectMucus-penetrating liposomesen_US
dc.subjectInterferonen_US
dc.subjectHuman papilloma virusen_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Farmakologi: 728en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710::Pharmacology: 728en_US
dc.titlePEGylated liposomes for topical vaginal therapy improve delivery of interferon alphaen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record